Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib with chemotherapy in high-risk CRLF2-rearranged or JAK-mutant B-ALL
NCT02723994Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2016
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ruxolitinib in acute lymphoblastic leukemia (ALL), sponsored by Incyte. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02723994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723994.